Catalyst
Slingshot members are tracking this event:
Paratek (PRTK) Plans to Submit New Drug Application in H1 2018 for Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 03, 2018
Occurred Source:
http://investor.paratekpharma.com/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2324587
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
New Drug Application, Omadacycline, Community Acquired Bacterial Pneumonia, Cabp, Fda
